Dx & Vx Co Ltd
Company Profile
Business description
Dx & Vx Co Ltd is a bio-healthcare company operating in the following business segments: Medical Diagnosis, Healthcare, and New Drug Development. The majority of its revenue is generated from the Healthcare segment, which utilizes diagnostic technology to provide integrated biohealthcare solutions for microbiome-based diseases, and offers health functional foods for prevention, over-the-counter and prescription drugs for treatment, and lifestyle and hygiene products for management. The Medical Diagnosis segment provides preimplantation, prenatal, neonatal, and adult genomic testing and microbiome analysis services, and the New Drug Development business is involved in the research and development of COVID vaccines and treatment, microbiome respiratory vaccine, and mRNA anticancer vaccine.
Contact
173 Digital-ro
1003, 10th Floor, Elysia Building
Geumcheon-gu
Gasan-dong
Seoul
KORT: +82 28908700
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
89
Stocks News & Analysis
stocks
Pure-play data center share raises capital to fund AI demand
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,978.80 | 34.20 | -0.38% |
| CAC 40 | 8,338.81 | 39.05 | -0.47% |
| DAX 40 | 24,830.98 | 84.51 | -0.34% |
| Dow JONES (US) | 52,146.42 | 406.55 | -0.77% |
| FTSE 100 | 10,600.37 | 28.13 | 0.27% |
| HKSE | 24,562.24 | 446.36 | -1.78% |
| NASDAQ | 25,520.24 | 361.70 | -1.40% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,694.68 | 79.90 | 0.59% |
| S&P 500 | 7,457.69 | 76.08 | -1.01% |
| S&P/ASX 200 | 8,796.70 | 20.10 | -0.23% |
| SSE Composite Index | 3,764.15 | 118.26 | -3.05% |